Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 102 clinical trials
A Study of CA-4948 in Patients With Relapsed or Refractory Hematologic Malignancies

CA-4948 either as monotherapy (Part A1) or in combination with ibrutinib for nonHodgkin' s Lymphoma (NHL), macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) and chronic lymphocytic leukemia (CLL

  • 17 views
  • 12 May, 2021
  • 11 locations
Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

This phase I trial studies the best dose of ibrutinib when given together with pembrolizumab in treating patients with stage III-IV melanoma that cannot be removed by surgery. Immunotherapy with

metastatic melanoma
platelet count
neutrophil count
metastasis
monoclonal antibodies
  • 8 views
  • 05 Jul, 2021
  • 2 locations
A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL

This is a prospective multicenter phase 2 study designed with the purpose to evaluate the response rate and safety of treatment with FCR/BR alternating with ibrutinib in treatment-naive patients

fludarabine
lymphoid leukemia
cyclophosphamide
chlorambucil
rituximab
  • 5 views
  • 22 Jan, 2021
  • 1 location
Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)

The investigator's want to find out if treatment with ibrutinib, rituximab, and lenalidomide are safe and better than the usual approach in patients with recurrent or refractory central nervous

  • 3 views
  • 18 Jun, 2021
  • 8 locations
Rituximab and Ibrutinib (RI) Versus Dexamethasone Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenstr m's Macroglobulinaemia

improve response outcome, durability and importantly, reduce toxicity for WM patients. This approach will be done using the drug Ibrutinib, which in combination with rituximab (RI) will be the

  • 0 views
  • 27 Jan, 2021
  • 7 locations
A Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Patients With Richter's Syndrome;

and the efficacy of the combination of cluster of anti differentiation antigen 20 (anti-CD20) antibody (e.g. Obinutuzumab or Rituximab) with Ibrutinib and/or Venetoclax have been already reported in

  • 0 views
  • 15 Dec, 2021
  • 4 locations
APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenstr m Macroglobulinemia

Phase Ib/II study of safety, tolerability, efficacy and PK of APG-2575 as a single agent or in combination with other therapeutic agents including ibrutinib or rituximab.

monoclonal antibody therapy
fever
measurable disease
rituximab
monoclonal antibodies
  • 0 views
  • 21 Jul, 2021
  • 5 locations
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide to people with certain B-cell lymphomas. Eligibility Adults ages 18 and older with relapsed and/or

neutrophil count
g-csf
b-cell lymphoma
flow cytometry
prednisone
  • 0 views
  • 17 Dec, 2021
  • 1 location
A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL

The purpose of this study is to determine the safety and recommended Phase 2 dose (RP2D) of JNJ-67856633 and ibrutinib in combination in participants with B cell non-Hodgkin lymphoma (NHL) and

ibrutinib
leukemia
chronic lymphocytic leukemia
lymphoma
  • 11 views
  • 08 Dec, 2021
  • 6 locations
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

This randomized phase III trial studies ibrutinib to see how well it works compared to placebo when given before and after stem cell transplant in treating patients with diffuse large B-cell

  • 149 views
  • 29 Jan, 2022
  • 105 locations